Japan's MHLW Approves Seven New Drugs Including Novartis' Alzheimer's Disease Patch
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved seven new drugs, including Novartis/Ono Pharmaceutical's Alzheimer's disease patch Exelon (rivastigmine)
You may also be interested in...
Forest Buys Clinical Data And Extends Its Antidepressant Portfolio
The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).